10:37 AM EST - Numinus Wellness Inc. : Announce that Cedar Clinical Research has begun studying COMP360 psilocybin therapy, an investigational new therapy for treatment-resistant depression (TRD), as part of the largest-ever international clinical study of psilocybin therapy. Dr. Paul Thielking, Chief Science Officer at Numinus, and the team have begun accepting people with TRD who fulfill certain eligibility criteria to join the study. Numinus Wellness Inc.
shares T.NUMI are trading up $0.03 at $0.26.
